• ProMIS Neurosciences (PMN) is trading 6.2% up today at $14.63 following a "strong-buy" rating initiated by Roth Capital.
  • The upgrade by Roth Capital on July 9, 2026, serves as a fresh, company-specific catalyst driving today's elevated momentum.
  • This analyst action contributes to continued speculative interest and reinforces a period of strength for the biotech company since late June.